Now I have all the evidence I need. Let me write the consolidated final review.

---

## Summary

MOCHA is described as a curated resource aggregating 10 publicly available SRT datasets (171 total samples) across multiple tissue types, with each sample purportedly paired with pathologist-derived spatial domain annotations and co-registered H&E images. The paper's central claim is that this resource fills a gap — enabling training and evaluation of multi-sample SRT methods that explicitly model cross-subject variability and batch effects.

---

## Strengths

- **Genuinely needed resource concept.** The paper correctly identifies that multi-subject SRT datasets with expert spatial annotations are scarce, and a centralized, well-documented resource would serve the community. The curation criteria are reasonable (public data + gene expression + coordinates + pathologist annotations + H&E image), and Table 1 provides a useful overview of cohort composition.

- **Non-trivial cohort coverage.** MOCHA aggregates 10 cohorts spanning 5 cancer types, normal brain, and mouse olfactory bulb, with platforms including both 10x Visium and ST. The 94-subject BC.TNBC cohort and 23-subject RCC.TLS cohort offer substantial multi-subject scale, and the inclusion of TLS-related datasets (KC, LC, RCC) covers an under-studied tissue structure relevant to immuno-oncology.

---

## Weaknesses

### Fatal

**1. No demonstration that the resource is usable for its stated purpose. [Fatal]**

The paper claims MOCHA enables "training and evaluation of multi-sample SRT methods" (abstract, Section 1) but provides zero experiments, zero baseline runs, and zero quantitative characterization of the annotation labels. Section 4 is a brief literature survey of three existing methods (BayeSMART, BASS, STAGATE) with no application of any method to MOCHA data. Section 3 is a generic preprocessing tutorial (normalization → HVG selection → Harmony batch correction → Crescendo) that does not describe what was applied to MOCHA or provide any dataset-specific output. For a dataset/resource paper, demonstrating basic utility is not a "nice-to-have" — it is the core validation. Without a single experiment, the reader cannot assess whether the annotations are consistent, whether the multi-sample structure poses tractable or degenerate problems, or whether the data is even usable. This is a structural deficiency: the paper is an announcement of intent, not a citable resource.

**2. No characterization of the central claimed asset — the pathologist annotations. [Fatal]**

The paper's primary differentiator from existing repositories is that each sample is "paired with domain annotations from expert pathologists." Yet the paper provides: (a) no information about how many pathologists were involved, (b) no inter-rater reliability assessment, (c) no annotation protocol description, (d) no count of labeled spots per domain per sample, (e) no label set names or hierarchy, and (f) no representative examples of annotations overlaid on H&E images. The only annotation detail is a single sentence in Section 4: "in a majority of the cancer studies… annotations can be grouped into four broad categories: immune, stroma, tumor, and normal," deferred to Supplementary Material. Without any characterization, the claim of "expert annotations" is an unsupported assertion, not a demonstrated asset.

### Major

**3. No comparison to or differentiation from existing SRT repositories.**

The introduction lists SORC, Aquila, SODB, STOmicsDB, SpatialDB, and STImage-1K4M, asserts that "multi-subject datasets with expert-generated spatial annotations remain limited," but provides no comparison table, feature matrix, or systematic discussion of what MOCHA covers that these resources do not. Since STImage-1K4M (cited by the authors) already aggregates SRT data with H&E images and includes multi-subject cancer cohorts, the onus is on the authors to substantiate what is new. Without this, the marginal contribution is unquantifiable.

**4. Mismatch between "multi-subject" framing and actual cohort composition.**

Several cohorts have very few subjects: MOB.ST has 1 subject (12 samples from the same animal — a repeated-measures single-subject design with no inter-subject variation), KC.TLS has 3, DLPFC has 3, and LC.TLS has 5. The paper frames the resource as supporting methods that "model biological heterogeneity alongside technical variation" (Section 1), but never discusses which cohorts are genuinely multi-subject and which are not. The single-subject MOB cohort cannot be used to evaluate cross-subject variability modeling. Seven of ten cohorts are breast cancer or TLS cancer variants, making the tissue range narrower than implied by "wide range of tissue types and disease contexts."

**5. No data access or format details.**

The abstract states MOCHA "is released in formats readily usable with Python and R," but the paper provides no download URL, no file format specification (HDF5? AnnData? Seurat object?), no license terms, no metadata schema, no file size estimates, and no example loading code. For a dataset paper, these are not optional — the resource cannot be evaluated or used without them.

### Minor

**6. Section 3 (preprocessing) is generic and not tied to MOCHA data.** The section describes standard SRT preprocessing workflows with general citations but does not specify which steps were applied to MOCHA, what normalization was used, whether the released data is raw or normalized, or how batch correction was handled for specific cohorts. Figure 2 is a pipeline illustration using KC_TLS_10x as an example, but no dataset-specific outputs are shown.

### Trivial

**7. Labeling inconsistency in Figure 1.** The figure caption and axis labels read "DLPC_10x" whereas Table 1 and the text use "DLPFC_10x" (dorsolateral prefrontal cortex).

---

## Nice-to-Haves

- Provide a baseline evaluation by applying at least one multi-sample method (e.g., BASS or STAGATE) to 2–3 cohorts, reporting domain identification metrics (ARI, NMI) against the pathologist annotations, and visually comparing inferred vs. annotated domains.
- Include representative H&E images with overlaid pathologist annotations for a few samples to give readers a qualitative sense of annotation granularity and quality.
- Disclose ethical/data provenance information for human tissue data (public and de-identified status, data use agreements).

---

## Removed Points

Points removed from the harsh critic's review because they are speculative, reflect scope creep, or are misattributed formatting issues:

- **"No description of annotation quality or protocol"** — Retained as Fatal #2 (fully verified).
- **"Annotation details deferred to Supplementary Material insufficient"** — Retained as part of Fatal #2.
- **"Data access and format details missing"** — Retained as Major #5 (fully verified, concrete).
- **"Ethical considerations missing"** — Moved to Nice-to-Haves; it is a reasonable suggestion but not a core weakness given the data is sourced from public repositories.
- **"BC.TNBC imbalance raises questions"** — The paper honestly reports the cohort size. This is a descriptive observation, not a weakness — large cohorts are a strength.
- **"Figure 1 box plots not interpretable without context"** — The figure caption and text describe the plots as showing molecular profiles. The interpretation is straightforward for the target audience.
- **"Section 4 is survey, doesn't use MOCHA data"** — Already captured in Fatal #1.
- **"Crescendo description out of place"** — This is editorial preference, not a substantive weakness. Including an alternative pipeline description is reasonable.
- **"The problems are structural in that no amount of added experiments would salvage the paper as written"** — This contradicts the critic's own strengthening suggestions. The paper would need substantial rewriting, but experiments would be the core fix. Not a separate point.
- **Strengths removed from Strength Finder:** "Standardized release formats for Python and R" — This is a claimed feature, not a demonstrated strength, since no format specifics are given. "Co-registered high-resolution H&E images" — This is a stated design feature but without demonstration or characterization, it's a claim, not evidence.

---

## Novel Insights

None beyond the paper's own contributions. The two reviews surface a clear structural issue: the paper identifies a real gap and has assembled relevant data, but provides no validation that the assembled resource actually fills the gap — no quality assessment of the annotations, no baseline experiments, no differentiation from prior resources. This is a well-known failure mode for dataset papers submitted before the resource is complete enough to be evaluated.

---

## Suggestions

1. Perform at least one baseline experiment applying a standard multi-sample clustering method (e.g., BASS, STAGATE, or BayeSMART) to 2–3 cohorts with contrasting subject counts (e.g., BC.TNBC with 94 subjects and KC.TLS with 3 subjects). Report ARI/NMI against pathologist annotations and visually compare inferred vs. ground-truth domains. This single addition would transform the paper from an announcement into a validated resource.
2. Provide a table comparing MOCHA against existing repositories (SORC, Aquila, SODB, STOmicsDB, SpatialDB, STImage-1K4M) on dimensions: number of multi-subject cohorts, availability of expert spatial annotations, H&E co-registration, file formats, and license. This would substantiate the gap claim.
3. Characterize the annotations: report number of labeled spots per domain per sample, label counts per cohort, and (if any) inter-annotator agreement metrics. Include representative H&E images with overlaid annotations.
4. Add a Data Access section specifying download URL(s), file formats (e.g., AnnData .h5ad), license (e.g., CC-BY 4.0), metadata schema, and a brief code snippet showing how to load a cohort.

---

## Score and Decision

**Round 1 bracket** (from calibration search on SRT dataset/resource papers): The paper is below 3.5. All anchors in the 4.0–6.5 range (spClust, HiBio-ST, STAMP) had experiments and evaluation. The 3.0-range anchors (STAGE, SQUINT, SPARC) were method papers rejected for limited novelty but were complete — they had experimental pipelines, benchmarks, and ablation studies. This paper lacks all of these.

**Round 2 narrowing** in the 1.0–4.0 range: Compared to BioDataLab (3.00, benchmark with 114 tasks and model evaluations) and OlymBio-Bench (2.00, benchmark with 363 questions and model evaluations), MOCHA is less complete — it has zero empirical content, zero data characterization, and no access details. It is comparable in completeness deficiency to OlymBio-Bench (2.00) but even weaker because OlymBio-Bench at least ran model evaluations and provided dataset statistics.

**Final score: 2.0.** The paper does not meet the evidentiary standard for a dataset release. Its core claims are unsupported by any experiments, annotation characterization, comparison to existing resources, or data access information. Identifying a gap and listing curated cohort names is a starting point, not a publication-ready contribution.

<score>2.0</score>
<decision>Reject</decision>